Add Company
Join Now

Anixa Biosciences Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Anixa Biosciences's estimated annual revenue is currently $2.5M per year.(i)
  • Anixa Biosciences's estimated revenue per employee is $155,000

Employee Data

  • Anixa Biosciences has 16 Employees.(i)
  • Anixa Biosciences grew their employee count by 7% last year.

Anixa Biosciences's People

NameTitleEmail/Phone
1
President, COO & CFOReveal Email/Phone
2
Chief Development OfficerReveal Email/Phone
3
President, COO & CFOReveal Email/Phone
4
Director, Clinical DevelopmentReveal Email/Phone
5
Senior Director Clinical DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is Anixa Biosciences?

Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company’s vaccine portfolio consists of a technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC). Anixa continually examines emerging technologies in complementary fields for further development and commercialization.

keywords:N/A

N/A

Total Funding

16

Number of Employees

$2.5M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.5M167%N/A
#2
$1.3M16N/AN/A
#3
$1.4M16N/AN/A
#4
$2M16-11%$57.8M
#5
$4.8M16-64%N/A